BioSpace News Archive

data also show fingolimod-treated patients had sig

Policy

Novartis Submits Application to FDA for Kymriah (Tisagenlecleucel) in Adult Patients With R/R DLBCL, Seeking Second Indication for First-Ever FDA Approved CAR-T Therapy

If approved, this would be the second indication for Kymriah.

October 31, 2017

·

13 min read

Business

OMRON Increases Net Earnings 91.2% to JPY30.3 Billion on Solid Gains in Core Industrial Automation Business

Net sales for the period increased 10.5%, to JPY410.5 billion.

October 31, 2017

·

3 min read

BGI’s MGI Tech Launches Two New NGS Platforms

MGI Tech launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200, at the 12th International Conference on Genomics in Shenzhen.

October 31, 2017

·

3 min read

Drug Development

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3.

October 31, 2017

·

8 min read

NeuroVive Signs Collaboration Agreement With University of Florida for TBI Biomarker Development

The research will be conducted at a laboratory at the University of Florida’s McKnight Brain Institute focused on neurotrauma, neuroproteomics and biomarkers research headed by Wang.

October 31, 2017

·

4 min read

Orexo Issues Bonds of SEK 325 Million and Confirms Fulfilment of Condition Under Notice of Early Redemption

Orexo has issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, due in November 2021.

October 31, 2017

·

2 min read

Business

Dr. Reddy’s Q2 and H1 FY18 Financial Results

Dr. Reddy’s Laboratories today announced its consolidated financial results for the second quarter and half year ended September 30, 2017 under International Financial Reporting Standards.

October 31, 2017

·

10 min read

Drug Development

DelMar Pharma Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

DelMar presented a poster entitled “DNA Damaging Agent Dianhydrogalactitol (VAL-083) Targets Homologous Repair (HR) Pathway and Suggests Combination Therapy with topoisomerase inhibitors and PARP inhibitors.”

October 31, 2017

·

6 min read

Business

Acorda Provides Financial and Pipeline Update for Third Quarter 2017

AMPYRA (dalfampridine) Extended Release Tablets, 10 mg - For the quarter ended September 30, 2017, the Company reported AMPYRA net revenue of $132.6 million compared to $128.8 million for the same quarter in 2016.

October 31, 2017

·

14 min read

BioForest

BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies

BioLife Solutions today announced both companies are providing their respective enhanced cold chain technologies for use in 8 active and pending clinical trials conducted by the Diabetes Center and Department of Surgery at the UCSF.

October 31, 2017

·

6 min read